Bouthaina S Dabaja

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2982079/publications.pdf

Version: 2024-02-01

		159525	161767
150	3,480	30	54
papers	citations	h-index	g-index

151	151	151	4187
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Adenocarcinoma of the small bowel. Cancer, 2004, 101, 518-526.	2.0	472
2	Modern Radiation Therapy for Nodal Non-Hodgkin Lymphomaâ€"Target Definition and Dose Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2014, 89, 49-58.	0.4	259
3	Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials. Journal of the American Academy of Dermatology, 2015, 72, 286-292.	0.6	156
4	Modern Radiation Therapy for Primary Cutaneous Lymphomas: Field and Dose Guidelines From theÂInternational Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2015, 92, 32-39.	0.4	150
5	Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2015, 92, 175-182.	0.4	110
6	Dosimetric advantages of a â€œbutterflyâ€•technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkinâ€™s lymphoma. Radiation Oncology, 2014, 9, 94.	1.2	90
7	Ultraâ€"lowâ€dose radiotherapy for definitive management of ocular adnexal Bâ€cell lymphoma. Head and Neck, 2017, 39, 1095-1100.	0.9	87
8	Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. Blood, 2018, 132, 1635-1646.	0.6	86
9	Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. Blood, 2018, 131, 84-94.	0.6	78
10	Intensity-modulated radiation therapy (IMRT) of cancers of the head and neck: Comparison of split-field and whole-field techniques. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1000-1005.	0.4	76
11	Cardiac atlas development and validation for automatic segmentation of cardiac substructures. Radiotherapy and Oncology, 2017, 122, 66-71.	0.3	76
12	Hyperâ€CVAD plus nelarabine in newly diagnosed adult Tâ€cell acute lymphoblastic leukemia and Tâ€lymphoblastic lymphoma. American Journal of Hematology, 2018, 93, 91-99.	2.0	74
13	Encouraging activity for R-CHOP in advanced stage nodular lymphocyteâ€"predominant Hodgkin lymphoma. Blood, 2017, 130, 472-477.	0.6	65
14	A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma. Scientific Reports, 2019, 9, 1322.	1.6	62
15	Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. British Journal of Haematology, 2017, 178, 403-412.	1.2	57
16	Treating Leukemia in the Time of COVID-19. Acta Haematologica, 2021, 144, 132-145.	0.7	57
17	The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma. Cancer, 2002, 94, 2738-2744.	2.0	55
18	Single-Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated With Immunochemotherapy in the Setting of Response Assessment by 18Fluorodeoxyglucose Positron Emission Tomography. International Journal of Radiation Oncology Biology Physics, 2015, 92, 113-121.	0.4	50

#	Article	IF	Citations
19	Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathology, 2015, 28, 1555-1573.	2.9	48
20	Double epigenetic modulation of highâ€dose chemotherapy with azacitidine and vorinostat for patients with refractory or poorâ€risk relapsed lymphoma. Cancer, 2016, 122, 2680-2688.	2.0	48
21	Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biology of Blood and Marrow Transplantation, 2015, 21, 1914-1920.	2.0	46
22	Retrospective Analysis of Prognostic Factors inÂ187 Cases of Transformed Mycosis Fungoides. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 49-56.	0.2	44
23	Radiation for diffuse large <scp>B</scp>â€cell lymphoma in the rituximab era: Analysis of the <scp>N</scp>ational <scp>C</scp>omprehensive <scp>C</scp>ancer <scp>N</scp>etwork lymphoma outcomes project. Cancer, 2015, 121, 1032-1039.	2.0	39
24	Preâ€treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. British Journal of Haematology, 2018, 180, 545-549.	1.2	38
25	Benefit of Consolidative Radiation Therapy for Primary Bone Diffuse Large B-Cell Lymphoma. International Journal of Radiation Oncology Biology Physics, 2015, 92, 122-129.	0.4	37
26	Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants inÂPatients With SÃ©zary Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e83-e93.	0.2	37
27	Radiation for Hodgkin's Lymphoma in Young Female Patients: A New Technique to Avoid the Breasts and Decrease the Dose to the Heart. International Journal of Radiation Oncology Biology Physics, 2011, 79, 503-507.	0.4	36
28	Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncology, 2016, 2, 1065.	3.4	36
29	NCCN GuidelinesÂ® Insights: Hodgkin Lymphoma, Version 2.2022. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 322-334.	2.3	35
30	Primary cutaneous B-cell lymphoma (non-leg type) has excellent outcomes even after very low dose radiation as single-modality therapy. Leukemia and Lymphoma, 2016, 57, 34-38.	0.6	34
31	Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. International Journal of Radiation Oncology Biology Physics, 2019, 104, 447-455.	0.4	31
32	Dorsal column myelopathy after intrathecal chemotherapy for leukemia. American Journal of Hematology, 2017, 92, 155-160.	2.0	30
33	Coronary Artery Dose-Volume Parameters Predict Risk of Calcification After Radiation Therapy. Journal of Cardiovascular Imaging, 2019, 27, 268.	0.2	30
34	Modern Radiation Therapy for Extranodal Nasal-Type NK/T-cell Lymphoma: Risk-Adapted Therapy, Target Volume, and Dose Guidelines from the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1064-1081.	0.4	26
35	Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma. Neuro-Oncology, 2016, 18, 575-581.	0.6	24
36	Longâ€term followâ€up of salvage therapy using a combination of inotuzumab ozogamicin and miniâ€“hyperâ€CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia. Cancer, 2021, 127, 2025-2038.	2.0	24

#	Article	IF	Citations
37	Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP.. Blood, 2010, 116, 2812-2812.	0.6	24
38	Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy. Cancer, 2003, 98, 1021-1028.	2.0	23
39	Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 101, 530-540.	0.4	23
40	Positron emission tomographyâ€“computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Advances, 2018, 2, 1334-1343.	2.5	23
41	Comprehensive Craniospinal Radiation for Controlling Central Nervous System Leukemia. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1119-1125.	0.4	22
42	Craniospinal irradiation prior to stem cell transplant for hematologic malignancies with CNS involvement: Effectiveness and toxicity after photon or proton treatment. Practical Radiation Oncology, 2017, 7, e401-e408.	1.1	21
43	Radiation Therapy Is an Effective Modality in the Treatment of Mantle Cell Lymphoma, Even in Heavily Pretreated Patients. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 474-479.	0.2	20
44	Mitigating the impact of COVID-19 on oncology: Clinical and operational lessons from a prospective radiation oncology cohort tested for COVID-19. Radiotherapy and Oncology, 2020, 148, 252-257.	0.3	20
45	Importance of Esophagogastroduodenoscopy in the Evaluation of Non-Gastrointestinal Mucosa-Associated Lymphoid Tissue Lymphoma. Cancer Journal (Sudbury, Mass), 2003, 9, 321-324.	1.0	19
46	Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. Frontiers in Oncology, 2021, 11, 648655.	1.3	19
47	Radiation Therapy Planning for Early-Stage Hodgkin Lymphoma: Experience of the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2015, 92, 144-152.	0.4	18
48	A multiâ€institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. Cancer, 2017, 123, 1363-1371.	2.0	18
49	Factors associated with risk of central nervous system relapse in patients with nonâ€core binding factor acute myeloid leukemia. American Journal of Hematology, 2017, 92, 924-928.	2.0	17
50	Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e41-e50.	0.2	17
51	ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma. Journal of the American College of Radiology, 2014, 11, 1026-1033.e3.	0.9	16
52	Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. American Journal of Hematology, 2016, 91, 894-899.	2.0	15
53	Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2018, 24, 1602-1609.	2.0	15
54	Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1146-1154.	0.4	15

#	Article	IF	Citations
55	Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma. American Journal of Surgical Pathology, 2018, 42, 492-499.	2.1	14
56	Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. Leukemia and Lymphoma, 2020, 61, 171-175.	0.6	14
57	Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2017, 58, 2833-2844.	0.6	13
58	Daily CT guidance improves target coverage during definitive radiation therapy for gastric MALT lymphoma. Practical Radiation Oncology, 2017, 7, e471-e478.	1.1	13
59	Deep-Inspiration Breath-Hold Intensity Modulated Radiation Therapy to the Mediastinum for Lymphoma Patients: Setup Uncertainties and Margins. International Journal of Radiation Oncology Biology Physics, 2018, 100, 254-262.	0.4	13
60	Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 122-128.	0.2	12
61	Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure. Leukemia and Lymphoma, 2018, 59, 2896-2903.	0.6	12
62	Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood Advances, 2019, 3, 1356-1367.	2.5	12
63	Radiation Oncology Strategies to Flatten the Curve During the Coronavirus Disease 2019 (COVID-19) Pandemic: Experience From a Large Tertiary Cancer Center. Advances in Radiation Oncology, 2020, 5, 567-572.	0.6	12
64	Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 244-250.	0.2	11
65	Effect of Deep Inspiration Breath Hold on Normal Tissue Sparing With Intensity Modulated Radiation Therapy Versus Proton Therapy for Mediastinal Lymphoma. Advances in Radiation Oncology, 2020, 5, 1255-1266.	0.6	11
66	Clinical Implications of PET-Negative Residual Disease At the Completion of Chemotherapy for Diffuse Large B-Cell Lymphoma. Blood, 2011, 118, 2695-2695.	0.6	11
67	Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score. International Journal of Radiation Oncology Biology Physics, 2017, 97, 333-338.	0.4	10
68	Decreased heart dose with deep inspiration breath hold for the treatment of gastric lymphoma with IMRT. Clinical and Translational Radiation Oncology, 2020, 24, 79-82.	0.9	10
69	New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. Haematologica, 2020, 105, e355-e357.	1.7	10
70	ACR Appropriateness CriteriaÂ® Diffuse Large B-Cell Lymphoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 610-620.	0.6	9
71	Changes in treatment patterns and impact of radiotherapy for early stage diffuse large B cell lymphoma after Rituximab: A population-based analysis. Radiotherapy and Oncology, 2016, 120, 150-155.	0.3	9
72	Treatment of Early-Stage Unfavorable Hodgkin Lymphoma: Efficacy and Toxicity of 4 Versus 6 Cycles of ABVD Chemotherapy With Radiation. International Journal of Radiation Oncology Biology Physics, 2016, 96, 110-118.	0.4	9

#	Article	IF	Citations
73	Effectiveness of low-dose radiation for primary cutaneous anaplastic large cell lymphoma. Advances in Radiation Oncology, 2017, 2, 363-369.	0.6	9
74	Earlyâ€stage Hodgkin lymphoma outcomes after combined modality therapy according to the postâ€chemotherapy 5â€point score: can residual petâ€positive disease be cured with radiotherapy alone?. British Journal of Haematology, 2017, 179, 488-496.	1.2	9
75	Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. Advances in Radiation Oncology, 2018, 3, 639-646.	0.6	9
76	Outcome of relapsed and refractory nodular lymphocyteâ€predominant Hodgkin lymphoma: a North American analysis. British Journal of Haematology, 2021, 192, 560-567.	1.2	9
77	Positron Emission Tomography/Computed Tomography Findings During Therapy Predict Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy Alone but Not in Those Who Receive Consolidation Radiation. International Journal of Radiation Oncology Biology Physics, 2014, 89, 384-391.	0.4	8
78	In the Battle Between Protons and Photons for Hematologic Malignancies, the Patient Must Win. International Journal of Radiation Oncology Biology Physics, 2016, 95, 43-45.	0.4	8
79	Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. JAMA Network Open, 2020, 3, e2013935.	2.8	8
80	Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated?. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e465-e469.	0.2	7
81	Frontline antibiotic therapy for earlyâ€stage Helicobacter pylori â€negative gastric MALT lymphoma. American Journal of Hematology, 2019, 94, E150-E153.	2.0	7
82	Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e51-e61.	0.2	7
83	Curcumin for the treatment of tumor-stage mycosis fungoides. Dermatologic Therapy, 2017, 30, e12511.	0.8	7
84	Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma?. International Journal of Radiation Oncology Biology Physics, 2016, 96, 951-958.	0.4	6
85	Using benchmarked lung radiation dose constraints to predict pneumonitis risk: Developing a nomogram for patients with mediastinal lymphoma. Advances in Radiation Oncology, 2018, 3, 372-381.	0.6	6
86	Multi-institutional Investigation: Circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides. Radiotherapy and Oncology, 2019, 131, 88-92.	0.3	6
87	Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease. Blood Advances, 2020, 4, 2064-2072.	2.5	6
88	Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria. International Journal of Radiation Oncology Biology Physics, 2021, 111, 36-44.	0.4	6
89	Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma. Blood, 2019, 134, 1609-1609.	0.6	6
90	Successful treatment of a free-moving abdominal mass with radiation therapy guided by cone-beam computed tomography: a case report. Journal of Medical Case Reports, 2010, 4, 329.	0.4	5

#	Article	IF	Citations
91	Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions. Advances in Radiation Oncology, 2017, 2, 370-380.	0.6	5
92	The Challenges of Applying Radiation in Primary Central Nervous System Lymphoma. International Journal of Radiation Oncology Biology Physics, 2020, 107, 398-400.	0.4	5
93	Partial omission of bleomycin for earlyâ€stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?. EJHaem, 2020, 1, 272-276.	0.4	5
94	Secondary central nervous system diffuse large cell lymphoma: an opportunity for radiation therapy to improve outcomes. Leukemia and Lymphoma, 2021, 62, 1-4.	0.6	5
95	Double Hit Lymphoma: M.D. Anderson Experience. Blood, 2013, 122, 1776-1776.	0.6	5
96	The Prognostic Value of Interim PET Scan in Patients with Classical Hodgkin Lymphoma. Blood, 2012, 120, 1529-1529.	0.6	5
97	An unusual case of cytotoxic peripheral T-cell lymphoma. JAAD Case Reports, 2015, 1, 257-260.	0.4	4
98	Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma With Bulky Disease. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 664-670.e2.	0.2	4
99	Primary cutaneous CD4+ smallâ€•to mediumâ€sized pleomorphic Tâ€•cell lymphoproliferative disorder in a pediatric patient successfully treated with lowâ€dose radiation. Pediatric Dermatology, 2019, 36, e23-e26.	0.5	4
100	Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria. Leukemia and Lymphoma, 2021, 62, 1057-1065.	0.6	4
101	MALT Lymphoma of the Urinary Bladder Shows a Dramatic Female Predominance, Uneven Geographic Distribution, and Possible Infectious Etiology. Research and Reports in Urology, 2021, Volume 13, 49-62.	0.6	4
102	The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leukemia and Lymphoma, 2021, 62, 1361-1369.	0.6	4
103	Early Stage Extranodal Follicular Lymphoma: Characteristics, Management, and Outcomes. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 381-389.	0.2	3
104	Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement. Leukemia and Lymphoma, 2020, 61, 2980-2984.	0.6	3
105	Daily computed tomography image guidance: Dosimetric advantages outweigh low-dose radiation exposure for treatment of mediastinal lymphoma. Radiotherapy and Oncology, 2020, 152, 14-18.	0.3	3
106	Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up. Blood Cancer Journal, 2021, 11, 17.	2.8	3
107	Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 641-641.	0.6	3
108	Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports. Journal of Medical Case Reports, 2016, 10, 209.	0.4	2

#	Article	IF	Citations
109	Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy. Leukemia and Lymphoma, 2018, 59, 2650-2659.	0.6	2
110	Coincident primary breast lymphoma and gastrointestinal stromal tumor: case series and molecular mechanisms. OncoTargets and Therapy, 2018, Volume 11, 8937-8942.	1.0	2
111	Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy. Leukemia and Lymphoma, 2019, 60, 2432-2440.	0.6	2
112	Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PETâ€“CT-documented First Remission. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 533-541.	0.2	2
113	Postâ€transplantation donorâ€derived Sezary syndrome in a patient with <scp>A91V PRF1</scp> variant hemophagocytic lymphohistiocytosis. American Journal of Hematology, 2021, 96, E350-E353.	2.0	2
114	MALT lymphoma of the tongue: An unusual site that may present a diagnostic challenge. Annals of Diagnostic Pathology, 2022, 56, 151841.	0.6	2
115	Assessment of Lymphoma and Other Hematologic Malignancies Training Needs Among Radiation Oncology Residents: a Brief Report. Journal of Cancer Education, 2023, 38, 201-205.	0.6	2
116	Incidence and predictors of Lhermitteâ€™s sign among patients receiving mediastinal radiation for lymphoma. Radiation Oncology, 2015, 10, 206.	1.2	1
117	Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma. Leukemia and Lymphoma, 2016, 57, 2612-2618.	0.6	1
118	Primary Cutaneous Peripheral T-Cell Lymphoma in a Sporotrichoid Pattern: A Case Report. Journal of Cutaneous Medicine and Surgery, 2017, 21, 568-571.	0.6	1
119	Radiotherapy in Patients with Mycosis Fungoides and Central Nervous System Involvement. Case Reports in Oncology, 2018, 11, 721-728.	0.3	1
120	Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma. Leukemia and Lymphoma, 2019, 60, 3258-3265.	0.6	1
121	Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) without Post-ASCT Maintenance, in Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM. Blood, 2015, 126, 1980-1980.	0.6	1
122	Either Combined-Modality Or Radiotherapy Alone Provide Favorable Outcome In Stage I-II Mantle Cell Lymphoma: A Report Of 82 Patients From The International Lymphoma Radiation Oncology Group (ILROG). Blood, 2013, 122, 4292-4292.	0.6	1
123	Association of Vitamin D Deficiency with Inferior Treatment Outcomes in Patients with Newly Diagnosed Classic Hodgkin Lymphoma: MD Anderson Cancer Center Experience. Blood, 2020, 136, 27-28.	0.6	1
124	CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. Blood, 2020, 136, 23-25.	0.6	1
125	Optimizing treatment for nasal NK T-cell lymphoma. Leukemia and Lymphoma, 2016, 57, 2487-2488.	0.6	0
126	Rainbow IMRT and Volumetric Imaging for Anterior Mesenteric Targets. Practical Radiation Oncology, 2019, 9, 147-152.	1.1	0

#	Article	IF	Citations
127	Postâ€<scp>ABVD</scp> biopsy results, and not postâ€<scp>ABVD FDG</scp>â€<scp>PET</scp> results, predict outcome in earlyâ€stage Hodgkin lymphoma: response to Adams and Kwee. British Journal of Haematology, 2019, 184, 292-293.	1.2	0
128	Would Negative Interim PET Be Enough to Omit Radiation in Patients With Early Hodgkin Lymphoma? The Answer Is No. International Journal of Radiation Oncology Biology Physics, 2020, 106, 16-17.	0.4	0
129	Continuous Decline in Second Malignancy Occurrence in Patients with Hodgkin Lymphoma; Analysis of 1670 Patients Over the Past 5 Decades. Blood, 2011, 118, 2694-2694.	0.6	0
130	Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 213-213.	0.6	0
131	Clinical Characteristics and Outcomes of Patients with Hodgkin Lymphoma with Central Nervous System Involvement: An International Multicenter Collaboration. Blood, 2015, 126, 3865-3865.	0.6	0
132	Radiation Pneumonitis Risk after Bleomycin Toxicity in Hodgkin Lymphoma Patients. Blood, 2015, 126, 1511-1511.	0.6	0
133	Maintenance Rituximab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) in the First Line Setting or at Relapse. Blood, 2019, 134, 5291-5291.	0.6	0
134	High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) with Consolidative Radiation Therapy (RT) for Relapsed or Refractory (R/R) Primary Mediastinal B-Cell Lymphoma (PMBCL): 20-Year Experience at MD Anderson Cancer Center (MDACC). Blood, 2020, 136, 32-33.	0.6	0
135	Long Term Outcome Patterns and Risk Factors for Early Mortality and Disease Progression in ALK-Positive Anaplastic Large Cell Lymphoma. Blood, 2021, 138, 2463-2463.	0.6	0
136	Outcomes of Patients with Extranodal Natural Killer/T-Cell Lymphoma: Single Institution Series. Blood, 2021, 138, 4536-4536.	0.6	0
137	Phase II Trial of Response Adapted Ultra Low Dose (ULD) Orbital Radiation Therapy for Indolent B Cell Lymphoma. Blood, 2021, 138, 3526-3526.	0.6	0
138	Association of Epstein-Barr Virus with Advanced Stage and Survival Outcomes in Classic Hodgkin's Lymphoma. Blood, 2020, 136, 37-38.	0.6	0
139	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2020, 136, 22-22.	0.6	0
140	Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. Blood, 2020, 136, 17-18.	0.6	0
141	Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis. Blood, 2020, 136, 42-43.	0.6	0
142	Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study. Blood, 2020, 136, 39-41.	0.6	0
143	Association of Smoking with Advanced Stage and Survival Outcomes in Classic Hodgkin's Lymphoma. Blood, 2020, 136, 34-35.	0.6	0
144	Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. Blood, 2020, 136, 45-47.	0.6	0

#	Article	IF	Citations
145	Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse. Blood, 2020, 136, 36-38.	0.6	0
146	Brentuximab Vedotin with Chemotherapy in Frontline Treatment of Classic Hodgkin Lymphoma Nodular Sclerosis Syncytial Variant. Blood, 2020, 136, 28-29.	0.6	0
147	Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. Blood, 2020, 136, 27-28.	0.6	0
148	Prognostic Value of Delta Lymphocyte Index (DLIx) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy. Blood, 2020, 136, 23-24.	0.6	0
149	Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. Blood, 2020, 136, 40-41.	0.6	0
150	Real Life Treatment Alterations of Frontline Therapies in Classic Hodgkin's Lymphoma. Blood, 2020, 136, 23-24.	0.6	0